These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 32444995)

  • 21. Triptolide attenuates pressure overload-induced myocardial remodeling in mice via the inhibition of NLRP3 inflammasome expression.
    Li R; Lu K; Wang Y; Chen M; Zhang F; Shen H; Yao D; Gong K; Zhang Z
    Biochem Biophys Res Commun; 2017 Mar; 485(1):69-75. PubMed ID: 28202417
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combination Treatment With Antihypertensive Agents Enhances the Effect of Qiliqiangxin on Chronic Pressure Overload-induced Cardiac Hypertrophy and Remodeling in Male Mice.
    Ye Y; Gong H; Wang X; Wu J; Wang S; Yuan J; Yin P; Jiang G; Li Y; Ding Z; Zhang W; Zhou J; Ge J; Zou Y
    J Cardiovasc Pharmacol; 2015 Jun; 65(6):628-39. PubMed ID: 25806688
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sacubitril/valsartan mitigates cardiac remodeling, systolic dysfunction, and preserves mitochondrial quality in a rat model of mitral regurgitation.
    Tantisuwat L; Saengklub N; Boonpala P; Kumphune S; Panyasing Y; Kalandakanond-Thongsong S; Kijtawornrat A
    Sci Rep; 2023 Jul; 13(1):11472. PubMed ID: 37455281
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sacubitril/Valsartan Averts Adverse Post-Infarction Ventricular Remodeling and Preserves Systolic Function in Rabbits.
    Torrado J; Cain C; Mauro AG; Romeo F; Ockaili R; Chau VQ; Nestler JA; Devarakonda T; Ghosh S; Das A; Salloum FN
    J Am Coll Cardiol; 2018 Nov; 72(19):2342-2356. PubMed ID: 30384891
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The selective NLRP3-inflammasome inhibitor MCC950 reduces myocardial fibrosis and improves cardiac remodeling in a mouse model of myocardial infarction.
    Gao R; Shi H; Chang S; Gao Y; Li X; Lv C; Yang H; Xiang H; Yang J; Xu L; Tang Y
    Int Immunopharmacol; 2019 Sep; 74():105575. PubMed ID: 31299609
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sacubitril/valsartan reduces susceptibility to atrial fibrillation by improving atrial remodeling in spontaneously hypertensive rats.
    Li Q; Fang Y; Peng DW; Li LA; Deng CY; Yang H; Kuang SJ; Li QQ; Zhang MZ; Zeng P; Zhang QH; Liu Y; Deng H; Wei W; Xue YM; Wu SL; Rao F
    Eur J Pharmacol; 2023 Aug; 952():175754. PubMed ID: 37182595
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sacubitril/valsartan (LCZ696) reduces myocardial injury following myocardial infarction by inhibiting NLRP3‑induced pyroptosis via the TAK1/JNK signaling pathway.
    Shen J; Fan Z; Sun G; Qi G
    Mol Med Rep; 2021 Sep; 24(3):. PubMed ID: 34296299
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reverse Cardiac Remodeling and Outcome After Initiation of Sacubitril/Valsartan.
    Januzzi JL; Camacho A; Piña IL; Rocha R; Williamson KM; Maisel AS; Felker GM; Prescott MF; Butler J; Solomon SD;
    Circ Heart Fail; 2020 Jun; 13(6):e006946. PubMed ID: 32482089
    [No Abstract]   [Full Text] [Related]  

  • 29. The Angiotensin II Receptor Neprilysin Inhibitor LCZ696 Inhibits the NLRP3 Inflammasome By Reducing Mitochondrial Dysfunction in Macrophages and Alleviates Dextran Sulfate Sodium-induced Colitis in a Mouse Model.
    Chiu HW; Wu CH; Lin WY; Wong WT; Tsai WC; Hsu HT; Ho CL; Cheng SM; Cheng CC; Yang SP; Li LH; Hua KF
    Inflammation; 2024 Apr; 47(2):696-717. PubMed ID: 38319541
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sacubitril/Valsartan Improves Left Ventricular Function in Chronic Pressure Overload Independent of Intact Cyclic Guanosine Monophosphate-dependent Protein Kinase I Alpha Signaling.
    Tam K; Richards DA; Aronovitz MJ; Martin GL; Pande S; Jaffe IZ; Blanton RM
    J Card Fail; 2020 Sep; 26(9):769-775. PubMed ID: 32464187
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Baicalein attenuates angiotensin II-induced cardiac remodeling via inhibition of AKT/mTOR, ERK1/2, NF-κB, and calcineurin signaling pathways in mice.
    Wang AW; Song L; Miao J; Wang HX; Tian C; Jiang X; Han QY; Yu L; Liu Y; Du J; Xia YL; Li HH
    Am J Hypertens; 2015 Apr; 28(4):518-26. PubMed ID: 25362112
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Puerarin protects against myocardial ischemia/reperfusion injury by inhibiting inflammation and the NLRP3 inflammasome: The role of the SIRT1/NF-κB pathway.
    Wang ZK; Chen RR; Li JH; Chen JY; Li W; Niu XL; Wang FF; Wang J; Yang JX
    Int Immunopharmacol; 2020 Dec; 89(Pt B):107086. PubMed ID: 33068868
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dapagliflozin and Ticagrelor Have Additive Effects on the Attenuation of the Activation of the NLRP3 Inflammasome and the Progression of Diabetic Cardiomyopathy: an AMPK-mTOR Interplay.
    Chen H; Tran D; Yang HC; Nylander S; Birnbaum Y; Ye Y
    Cardiovasc Drugs Ther; 2020 Aug; 34(4):443-461. PubMed ID: 32335797
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sacubitril/valsartan ameliorates cardiac hypertrophy and preserves diastolic function in cardiac pressure overload.
    Nordén ES; Bendiksen BA; Andresen H; Bergo KK; Espe EK; Hasic A; Hauge-Iversen IM; Veras I; Hussain RI; Sjaastad I; Christensen G; Cataliotti A
    ESC Heart Fail; 2021 Apr; 8(2):918-927. PubMed ID: 33497525
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ginsenoside Rg3 attenuates angiotensin II-induced myocardial hypertrophy through repressing NLRP3 inflammasome and oxidative stress via modulating SIRT1/NF-κB pathway.
    Ren B; Feng J; Yang N; Guo Y; Chen C; Qin Q
    Int Immunopharmacol; 2021 Sep; 98():107841. PubMed ID: 34153662
    [TBL] [Abstract][Full Text] [Related]  

  • 36. SGLT-2 Inhibition with Dapagliflozin Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the Development of Diabetic Cardiomyopathy in Mice with Type 2 Diabetes. Further Augmentation of the Effects with Saxagliptin, a DPP4 Inhibitor.
    Ye Y; Bajaj M; Yang HC; Perez-Polo JR; Birnbaum Y
    Cardiovasc Drugs Ther; 2017 Apr; 31(2):119-132. PubMed ID: 28447181
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Strain-selective efficacy of sacubitril/valsartan on carotid fibrosis in response to injury in two inbred mouse strains.
    Korshunov VA; Quinn B; Faiyaz A; Ahmed R; Sowden MP; Doyley MM; Berk BC
    Br J Pharmacol; 2019 Aug; 176(15):2795-2807. PubMed ID: 31077344
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacodynamic and pharmacokinetic effects of S086, a novel angiotensin receptor neprilysin inhibitor.
    Sun J; Xu W; Hua H; Xiao Y; Chen X; Gao Z; Li S; Jing X; Du F; Sun G
    Biomed Pharmacother; 2020 Sep; 129():110410. PubMed ID: 32570118
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The reverse remodeling response to sacubitril/valsartan therapy in heart failure with reduced ejection fraction.
    Martens P; Beliën H; Dupont M; Vandervoort P; Mullens W
    Cardiovasc Ther; 2018 Aug; 36(4):e12435. PubMed ID: 29771478
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sacubitril/Valsartan in Real-Life Practice: Experience in Patients with Advanced Heart Failure and Systematic Review.
    Moliner-Abós C; Rivas-Lasarte M; Pamies Besora J; Fluvià-Brugues P; Solé-González E; Mirabet S; López López L; Brossa V; Pirla MJ; Mesado N; Álvarez-García J; Roig E
    Cardiovasc Drugs Ther; 2019 Jun; 33(3):307-314. PubMed ID: 30820802
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.